Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | FABP7 | O15540 | 1/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468684 | 1.00 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL31031901 | 1.00 | KMT2A (0.72) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL1660910 | 0.96 | KMT2A (0.74) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29401182 | 0.94 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL6889085 | 0.94 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29458423 | 0.94 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL887559 | 0.94 | KMT2A (0.77) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL793384 | 0.91 | KMT2A (0.85) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL163534 | 0.91 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL8273302 | 0.90 | KMT2A (0.63) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20240400684-A1 | ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-12-05 | — | — | US | disclosed |
| CN-118255678-A | Ionizable lipid compound and application thereof | 荣灿生物医药技术(上海)有限公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024040169-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4212541-A1 | OLIGOSACCHARIDE-PROTEIN CONJUGATES AND THEIR INTERMEDIATES | Genzyme Corporation (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230167450-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | FLAGSHIP PIONEERING, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| EP-0939629-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1999-09-08 | — | — | EP | disclosed |
| EP-0789715-A4 | COMPLEMENTARILY BONDED TWO- AND THREE-DIMENSIONAL SUPRAMOLECULAR STRUCTURES | BURSTEIN LAB INC (US) | 1999-08-18 | — | — | EP | disclosed |
| EP-0880503-A1 | BALANOL ANALOGUES | Phytera Symbion ApS (DK) | 1998-12-02 | — | — | EP | disclosed |
| US-5718915-A | DRUG DELIVERY | BURSTEIN LABORATORIES, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1998003166-A1 | THIOL SULFONAMIDE METALLOPROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1998-01-29 | — | — | WO | disclosed |
| EP-0789715-A1 | COMPLEMENTARILY BONDED TWO- AND THREE-DIMENSIONAL SUPRAMOLECULAR STRUCTURES | BURSTEIN LABORATORIES, INC. (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997029091-A1 | BALANOL ANALOGUES | PHYTERA SYMBION APS (DK) | 1997-08-14 | — | — | WO | disclosed |
| WO-1996032841-A9 | NOVEL THERAPEUTIC BINDING MOLECULE COMPLEXES | — | 1996-12-27 | — | — | WO | disclosed |
| WO-1996032841-A1 | NOVEL THERAPEUTIC BINDING MOLECULE COMPLEXES | BURSTEIN LABORATORIES, INC. (US) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996013522-A1 | COMPLEMENTARILY BONDED TWO- AND THREE-DIMENSIONAL SUPRAMOLECULAR STRUCTURES | BURSTEIN LABORATORIES, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158156-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, SNRPE, DDX21 | KMT2A 3463/4885EPHX2 1615/4885FABP7 820/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | KMT2A 2167/4885EPHX2 2080/4885FABP7 1242/4885 |
| US-20230332145-A1 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | EFTUD2, DDX21, SNRPE | KMT2A 3085/4885EPHX2 1836/4885FABP7 877/4885 |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | EFTUD2, DDX21, SNRPE | KMT2A 3085/4885EPHX2 1836/4885FABP7 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.